We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
-1.01%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.36B
AUM Growth
-$447M
Cap. Flow
+$100M
Cap. Flow %
2.31%
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
20
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.6 years

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$183M
2
ARGX icon
argenx
ARGX
+$128M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$108M
4
JNJ icon
Johnson & Johnson
JNJ
+$97.3M
5
HUM icon
Humana
HUM
+$95M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$194M
2
BAX icon
Baxter International
BAX
+$149M
3
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$146M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$115M
5
ABBV icon
AbbVie
ABBV
+$109M

Sector Composition

Rank Sector Weight
1 Healthcare 95.61%
2 Miscellaneous 3.74%
3 Financials 0.54%
4 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LEGN icon
26
Legend Biotech
LEGN
$3.85B
$55M 1.26%
1,000,000
-95,000
-9% -$4.01M
2021 Q2
4 quarters
ARWR icon
27
Arrowhead Research
ARWR
$8.26B
$50.7M 1.16%
1,438,999
+483,999
+51% +$18.2M
2021 Q2
4 quarters
IMCR icon
28
Immunocore
IMCR
$1.52B
$50.4M 1.16%
1,350,000
-13,800
-1% -$448K
2021 Q1
5 quarters
NTRA icon
29
Natera
NTRA
$58.3B
$48.5M 1.11%
1,369,100
+69,100
+5% +$2.56M
2020 Q3
7 quarters
ITCI icon
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$44.3M 1.02%
+775,504
New +$44M
2022 Q2
0 quarters
IDYA icon
31
IDEAYA Biosciences
IDYA
$3.27B
$41M 0.94%
2,972,947
+282,947
+11% +$3.15M
2021 Q1
5 quarters
BLU
32
DELISTED
BELLUS Health Inc.
BLU
$39.4M 0.9%
4,265,000
+580,000
+16% +$4.74M
2020 Q4
6 quarters
ALT icon
33
Altimmune
ALT
$459M
$34.9M 0.8%
2,981,000
+116,000
+4% +$715K
2021 Q3
3 quarters
KZR icon
34
DELISTED
Kezar Life Sciences
KZR
$33.5M 0.77%
405,000
+53,200
+15% +$4.69M
2021 Q3
3 quarters
RNAM
35
DELISTED
Avidity Biosciences
RNAM
$30.2M 0.69%
2,080,200
+35,200
+2% +$524K
2021 Q3
3 quarters
KRTX icon
36
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$25.9M 0.59%
+204,570
New +$23.5M
2022 Q2
0 quarters
RVMD icon
37
Revolution Medicines
RVMD
$40.6B
$25.8M 0.59%
+1,325,000
New +$25.8M
2022 Q2
0 quarters
ARKG icon
38
ARK Genomic Revolution ETF
ARKG
$2.09B
$23.6M 0.54%
+750,000
New +$26.2M
2022 Q2
0 quarters
VIR icon
39
Vir Biotechnology
VIR
$1.77B
$19.3M 0.44%
758,211
-21,789
-3% -$509K
2021 Q2
4 quarters
NKTX icon
40
Nkarta
NKTX
$138M
$17.4M 0.4%
+1,414,082
New +$18.6M
2022 Q2
0 quarters
PHAT icon
41
Phathom Pharmaceuticals
PHAT
$607M
$16.2M 0.37%
1,919,800
-26,200
-1% -$269K
2021 Q4
2 quarters
CRBU icon
42
Caribou Biosciences
CRBU
$49.8M
$16M 0.37%
2,950,000
+130,933
+5% +$1M
2021 Q3
3 quarters
DCPH icon
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$15.8M 0.36%
+1,200,000
New +$13.2M
2022 Q2
0 quarters
NUVB icon
44
Nuvation Bio
NUVB
$1.67B
$15.7M 0.36%
4,855,000
-6
-0% -$26
2021 Q1
5 quarters
IOVA icon
45
Iovance Biotherapeutics
IOVA
$6.67B
$15.4M 0.35%
1,392,300
-4,650,919
-77% -$60.9M
2021 Q3
3 quarters
XENE icon
46
Xenon Pharmaceuticals
XENE
$3.32B
$13.7M 0.31%
+450,000
New +$13.6M
2022 Q2
0 quarters
SIBN icon
47
SI-BONE Inc
SIBN
$892M
$13.2M 0.3%
1,000,000
– –
2020 Q4
6 quarters
SPNE
48
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$11.4M 0.26%
2,010,000
– –
2021 Q2
4 quarters
ATEC icon
49
Alphatec Holdings
ATEC
$1.69B
$11.2M 0.26%
1,715,000
-1,020,600
-37% -$9.4M
2020 Q4
6 quarters
APLS icon
50
DELISTED
Apellis Pharmaceuticals
APLS
$9.72M 0.22%
215,000
+5,000
+2% +$228K
2022 Q1
1 quarter
1
2
3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
FGA
Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $626M AUM 199.29% 1-Year Est. Return

Avidity Partners Management's Q2 2022 Portfolio in Review

As of Q2 2022, Avidity Partners Management held 102 positions worth $4.36B, down 9.3% from $4.8B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management's Q2 2022 filing shows 10 new, 31 increased, 13 reduced and 20 closed positions. Its largest new stake was Eli Lilly: 610,000 shares worth $198M. The largest sale was Merck, an estimated $194M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Miscellaneous and Financials.

  • Avidity Partners Management's largest Q2 2022 buy was Eli Lilly: 610,000 shares worth $198M.
  • Avidity Partners Management added most to argenx in Q2 2022, an estimated $128M increase.
  • Avidity Partners Management's biggest Q2 2022 reduction was AbbVie, cutting an estimated $109M.
  • Avidity Partners Management fully exited Merck in Q2 2022, selling an estimated $194M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $4.36B portfolio in Q2 2022.
  • Avidity Partners Management opened 10 new positions and closed 20 in Q2 2022.
  • Avidity Partners Management's portfolio value fell 9.3% quarter-over-quarter to $4.36B.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.